Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-β signaling results in variable activation of human dermal fibroblasts

Dolivo,David  M.; Larson,Sara   A.; Dominko,Tanja

doi:10.3892/ijmm.2018.3949

Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-β signaling results in variable activation of human dermal fibroblasts

Authors:
- David M. Dolivo
- Sara A. Larson
- Tanja Dominko
View Affiliations

Affiliations: Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01609, USA
Published online on: October 23, 2018 https://doi.org/10.3892/ijmm.2018.3949
Pages: 325-335
Copyright: © Dolivo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast activation is a key step in the establishment of skin fibrosis induced by acute injury, and it is characterized by the differentiation of plastic resident tissue fibroblasts into contractile, extracellular matrix‑secreting myofibroblasts. As fibroblast activation must be regulated in vivo, fibroblasts receive signals from the surrounding environment that initiate their fibrotic program. Thus, the present study investigated the effects of mitogen‑activated protein kinase (MAPK) signaling pathways on fibroblast activation. It was demonstrated in primary human dermal fibroblasts that small molecule‑mediated inhibition of extracellular signal‑regulated kinase (ERK) and c‑Jun N‑terminal kinase (JNK) potentiated fibroblast activation, and that small molecule‑mediated inhibition of p38 antagonized fibroblast activation. ERK and JNK inhibition cooperatively enhanced fibroblast activation mediated by treatment with exogenous transforming growth factor (TGF)‑β1, and p38 inhibition antagonized ERK inhibitor‑mediated or JNK inhibitor‑mediated fibroblast activation. Transcript analysis demonstrated that ERK and JNK inhibitor‑mediated fibroblast activation was accompanied by distinct changes in the expression of TGF‑β‑associated ligands and receptors, and that p38 inhibitor‑mediated antagonism of fibroblast activation was accompanied by a distinct expression paradigm of TGF‑β‑associated genes, including upregulation of betaglycan. ERK inhibitor‑mediated and JNK inhibitor‑mediated fibroblast activation was partially antagonized by small molecule‑mediated inhibition of TGF‑β receptor (R)1, indicating that these mechanisms of fibroblast activation are partially dependent on TGF‑β/TGF‑βR signaling. These data collectively demonstrate and provide partial explanations of the varied effects and pathway dependencies of MAPK inhibitor‑mediated effects on fibroblast activation.

View Figures

View References

1	Wynn TA: Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 117:524–529. 2007. View Article : Google Scholar : PubMed/NCBI
2	Zeisberg M and Kalluri R: Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 304:C216–C225. 2013. View Article : Google Scholar :
3	Hinz B: Myofibroblasts. Exp Eye Res. 142:56–70. 2016. View Article : Google Scholar
4	Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
5	Mulsow JJ, Watson RW, Fitzpatrick JM and O’connell PR: Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 242:880–889. 2005. View Article : Google Scholar : PubMed/NCBI
6	Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF and Nikolic-Paterson DJ: The role of p38α mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol. 15:370–379. 2004. View Article : Google Scholar : PubMed/NCBI
7	Grella A, Kole D, Holmes W and Dominko T: FGF2 overrides TGFβ1-driven integrin ITGA11 expression in human dermal fibroblasts. J Cell Biochem. 117:1000–1008. 2016. View Article : Google Scholar
8	Wu W, Muchir A, Shan J, Bonne G and Worman HJ: Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation. 123:53–61. 2011. View Article : Google Scholar
9	Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF and Ricardo SD: Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-β1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol. 169:1527–1540. 2006. View Article : Google Scholar : PubMed/NCBI
10	See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S and Krum H: p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol. 44:1679–1689. 2004. View Article : Google Scholar : PubMed/NCBI
11	Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, Gunaje J, Otsu K and Davis J: Fibroblast-specific genetic manipulation of p38 Mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation. 136:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
12	Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, Yamagata H, Matsushita M, Seki T, Inagaki Y, et al: p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology. 38:879–889. 2003. View Article : Google Scholar : PubMed/NCBI
13	Meyer-Ter-Vehn T, Gebhardt S, Sebald W, Buttmann M, Grehn F, Schlunck G and Knaus P: p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human Tenon fibroblasts. Invest Ophthalmol Vis Sci. 47:1500–1509. 2006. View Article : Google Scholar : PubMed/NCBI
14	Sousa AM, Liu T, Guevara O, Stevens J, Fanburg BL, Gaestel M, Toksoz D and Kayyali US: Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem. 100:1581–1592. 2007. View Article : Google Scholar
15	Dolivo DM, Larson SA and Dominko T: FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts. J Dermatol Sci. 88:339–348. 2017. View Article : Google Scholar : PubMed/NCBI
16	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar
17	Kagan HM and Li W: Lysyl oxidase: Properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 88:660–672. 2003. View Article : Google Scholar : PubMed/NCBI
18	Burch ML, Zheng W and Little PJ: Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci. 68:97–107. 2011. View Article : Google Scholar
19	Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, Mclauchlan H, Klevernic I, Arthur JS, Alessi DR and Cohen P: The selectivity of protein kinase inhibitors: A further update. Biochem J. 408:297–315. 2007. View Article : Google Scholar : PubMed/NCBI
20	Maddaluno L, Urwyler C and Werner S: Fibroblast growth factors: Key players in regeneration and tissue repair. Development. 144:4047–4060. 2017. View Article : Google Scholar : PubMed/NCBI
21	Johnson KE and Wilgus TA: Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle). 3:647–661. 2014. View Article : Google Scholar :
22	Barrientos S, Stojadinovic O, Golinko MS, Brem H and Tomic-Canic M: Growth factors and cytokines in wound healing. Wound Repair Regen. 16:585–601. 2008. View Article : Google Scholar
23	Werner S and Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev. 83:835–870. 2003. View Article : Google Scholar : PubMed/NCBI
24	Krishna M and Narang H: The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 65:3525–3544. 2008. View Article : Google Scholar : PubMed/NCBI
25	Plotnikov A, Zehorai E, Procaccia S and Seger R: The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta. 1813.1619–1633. 2011.
26	Ihn H, Yamane K and Tamaki K: Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol. 20:247–255. 2005. View Article : Google Scholar
27	Galliher AJ and Schiemann WP: Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 67:3752–3758. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM and Derynck R: TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 26:3957–3967. 2007. View Article : Google Scholar : PubMed/NCBI
29	Chapnick DA, Warner L, Bernet J, Rao T and Liu X: Partners in crime: The TGFβ and MAPK pathways in cancer progression. Cell Biosci. 1:422011. View Article : Google Scholar
30	Xie L, Law BK, Chytil AM, Brown KA, Aakre ME and Moses HL: Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 6:603–610. 2004. View Article : Google Scholar : PubMed/NCBI
31	Gui T, Sun Y, Shimokado A and Muragaki Y: The roles of mitogen-activated protein kinase pathways in TGF-β-induced epithelial-mesenchymal transition. J Signal Transduct. 2012.289243:2012.
32	Selvamurugan N, Kwok S, Alliston T, Reiss M and Partridge NC: Transforming growth factor-beta1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem. 279:19327–19334. 2004. View Article : Google Scholar : PubMed/NCBI
33	Terai K, Call MK, Liu H, Saika S, Liu CY, Hayashi Y, Chikama T, Zhang J, Terai N, Kao CW and Kao WW: Crosstalk between TGF-beta and MAPK signaling during corneal wound healing. Invest Ophthalmol Vis Sci. 52:8208–8215. 2011. View Article : Google Scholar : PubMed/NCBI
34	Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL and Henson PM: Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-β. J Biol Chem. 277:14884–14893. 2002. View Article : Google Scholar : PubMed/NCBI
35	Kolosova I, Nethery D and Kern JA: Role of Smad2/3 and p38 MAP kinase in TGF-β1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol. 226:1248–1254. 2011. View Article : Google Scholar :
36	Nishida M, Okumura Y, Sato H and Hamaoka K: Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. Nephrol Dial Transplant. 23:2520–2524. 2008. View Article : Google Scholar : PubMed/NCBI
37	Raia V, Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Auricchio S, Cimmino M, Cavaliere M, Nardone M, Cesaro A, et al: Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax. 60:773–780. 2005. View Article : Google Scholar : PubMed/NCBI
38	Gao F, Wang Y, Li S, Wang Z, Liu C and Sun D: Inhibition of p38 mitogen-activated protein kinases attenuates renal interstitial fibrosis in a murine unilateral ureteral occlusion model. Life Sci. 167:78–84. 2016. View Article : Google Scholar : PubMed/NCBI
39	Sugiyama N, Kohno M and Yokoyama T: Inhibition of the p38 MAPK pathway ameliorates renal fibrosis in an NPHP2 mouse model. Nephrol Dial Transplant. 27:1351–1358. 2012. View Article : Google Scholar
40	Wilde JM, Gumucio JP, Grekin JA, Sarver DC, Noah AC, Ruehlmann DG, Davis ME, Bedi A and Mendias CL: Inhibition of p38 mitogen-activated protein kinase signaling reduces fibrosis and lipid accumulation after rotator cuff repair. J Shoulder Elbow Surg. 25:1501–1518. 2016. View Article : Google Scholar : PubMed/NCBI
41	López-Casillas F, Payne HM, Andres JL and Massagué J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol. 124:557–568. 1994. View Article : Google Scholar : PubMed/NCBI
42	Eickelberg O, Centrella M, Reiss M, Kashgarian M and Wells RG: Betaglycan Inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem. 277:823–829. 2002. View Article : Google Scholar
43	Hermida N, López B, González A, Dotor J, Lasarte JJ, Sarobe P, Borrás-Cuesta F and Díez J: A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res. 81:601–609. 2009. View Article : Google Scholar
44	Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Peñuelas I, Blanco G, Rodríguez C, Lechuga Mdel C, Greenwel P, et al: A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine. 22:12–20. 2003. View Article : Google Scholar : PubMed/NCBI
45	Santiago B, Gutierrez-Cañas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borrás-Cuesta F and Pablos JL: Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol. 125:450–455. 2005. View Article : Google Scholar : PubMed/NCBI
46	Ahn JY, Park S, Yun YS and Song JY: Inhibition of type III TGF-β receptor aggravates lung fibrotic process. Biomed Pharmacother. 64:472–476. 2010. View Article : Google Scholar : PubMed/NCBI
47	Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B and Chen X: JNK inhibitor SP600125 enhances TGF-β-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner. Mol Med Rep. 8:1623–1629. 2013. View Article : Google Scholar : PubMed/NCBI
48	Wu S, Kasisomayajula K, Peng J and Bancalari E: Inhibition of JNK enhances TGF-beta1-activated Smad2 signaling in mouse embryonic lung. Pediatr Res. 65:381–386. 2009. View Article : Google Scholar : PubMed/NCBI
49	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
50	Hough C, Radu M and Doré JJ: Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One. 7:e425132012. View Article : Google Scholar : PubMed/NCBI
51	Hayashida T, Decaestecker M and Schnaper HW: Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17:1576–1578. 2003. View Article : Google Scholar : PubMed/NCBI
52	Engel ME, McDonnell MA, Law BK and Moses HL: Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem. 274:37413–37420. 1999. View Article : Google Scholar : PubMed/NCBI
53	Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H, Sekimoto G, Seki T, Matsui H, Nishizawa M, et al: TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene. 23:7416–7429. 2004. View Article : Google Scholar : PubMed/NCBI
54	Qu K, Huang Z, Lin T, Liu S, Chang H, Yan Z, Zhang H and Liu C: New Insight into the anti-liver fibrosis effect of multi-targeted tyrosine kinase inhibitors: From molecular target to clinical trials. Front Pharmacol. 6:3002016. View Article : Google Scholar
55	Kompa AR: Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease. J Thorac Dis. 8:E1068–E1071. 2016. View Article : Google Scholar
56	Raghu G and Selman M: Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am Thoracic Soc. 191:252–254. 2015.
57	Hartmann JT, Haap M, Kopp HG and Lipp HP: Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab. 10:470–481. 2009. View Article : Google Scholar : PubMed/NCBI